Clinical Trials Browser

Phase 2 × Hereditary leiomyomatosis and renal cell cancer × Temozolomide × Clear all

NCT04603365 2023-05-17

Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

Phase 2 Withdrawn

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell